RCT of 58 patients with severe CRSwNP given mepolizumab alone or with FESS: both groups improved FEV1 (+3.5% and +3.4%), FVC, type 2 inflammation and symptoms; adding FESS gave greater gains in polyp score, congestion and symptom burden.
RCTn = 58
Tidemandsen et al. The Global Airways in Practice: Long-term Effects of Mepolizumab With or Without FESS on Type 2 Inflammation in Patients With CRSwNP